Nabil Elshafeey
Overview
Explore the profile of Nabil Elshafeey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
206
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pease M, Gersey Z, Ak M, Elakkad A, Kotrotsou A, Zenkin S, et al.
J Neurooncol
. 2022 Oct;
160(1):253-263.
PMID: 36239836
Purpose: Although glioblastoma (GBM) is the most common primary brain malignancy, few tools exist to pre-operatively risk-stratify patients by overall survival (OS) or common genetic alterations. We developed an MRI-based...
2.
Wu C, Jarrett A, Zhou Z, Elshafeey N, Adrada B, Candelaria R, et al.
Cancer Res
. 2022 Aug;
82(18):3394-3404.
PMID: 35914239
Significance: Integrating MRI data with biologically based mathematical modeling successfully predicts breast cancer response to chemotherapy, suggesting digital twins could facilitate a paradigm shift from simply assessing response to predicting...
3.
Jimenez J, Abdelhafez A, Mittendorf E, Elshafeey N, Yung J, Litton J, et al.
Eur J Radiol
. 2022 Feb;
149:110220.
PMID: 35193025
Purpose: We aimed to develop a predictive model based on pretreatment MRI radiomic features (MRIRF) and tumor-infiltrating lymphocyte (TIL) levels, an established prognostic marker, to improve the accuracy of predicting...
4.
Colen R, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, et al.
J Immunother Cancer
. 2021 Jul;
9(7).
PMID: 34315823
The need to identify biomarkers to predict immunotherapy response for rare cancers has been long overdue. We aimed to study this in our paper, 'Radiomics analysis for predicting pembrolizumab response...
5.
Colen R, Rolfo C, Ak M, Ayoub M, Ahmed S, Elshafeey N, et al.
J Immunother Cancer
. 2021 Apr;
9(4).
PMID: 33849924
Background: We present a radiomics-based model for predicting response to pembrolizumab in patients with advanced rare cancers. Methods: The study included 57 patients with advanced rare cancers who were enrolled...
6.
Elshafeey N, Kotrotsou A, Hassan A, Elshafei N, Hassan I, Ahmed S, et al.
Nat Commun
. 2019 Jul;
10(1):3170.
PMID: 31320621
Pseudoprogression (PsP) is a diagnostic clinical dilemma in cancer. In this study, we retrospectively analyse glioblastoma patients, and using their dynamic susceptibility contrast and dynamic contrast-enhanced perfusion MRI images we...
7.
Zinn P, Singh S, Kotrotsou A, Hassan I, Thomas G, Luedi M, et al.
Clin Cancer Res
. 2018 Jul;
24(24):6288-6299.
PMID: 30054278
Purpose: Radiomics is the extraction of multidimensional imaging features, which when correlated with genomics, is termed radiogenomics. However, radiogenomic biological validation is not sufficiently described in the literature. We seek...
8.
Elshafeey N, Hassan I, Zinn P, Colen R
Top Magn Reson Imaging
. 2017 Jan;
26(1):33-41.
PMID: 28079715
Radiogenomics is a relatively new and exciting field within radiology that links different imaging features with diverse genomic events. Genomics advances provided by the Cancer Genome Atlas and the Human...
9.
Colen R, Hassan I, Elshafeey N, Zinn P
Magn Reson Imaging Clin N Am
. 2016 Oct;
24(4):741-749.
PMID: 27742114
The new World Health Organization classification of brain tumors depends on combining the histologic light microscopy features of central nervous system (CNS) tumors with canonical genetic alterations. This integrated diagnosis...